ADU-1805
Multiple Solid Tumors
Phase 1Active
Key Facts
About Exelixis
Exelixis has evolved into a multi-platform cancer company over three decades, transitioning from early-stage development to commercial success with approved oncology treatments. The company operates through both small molecule discovery and biotherapeutics platforms, with a robust pipeline including next-generation TKIs and innovative biologics. Their strategic approach combines internal R&D capabilities with external partnerships to advance multiple clinical programs across various cancer types.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| BAY 1817080 | Bayer | Phase 1 |
| Zanzalintinib + nivolumab | Exelixis | Phase 1b/2 |
| Zanzalintinib + atezolizumab | Exelixis | Phase 1b/2 |
| XL309 | Exelixis | Phase 1 |
| XB010 | Exelixis | Phase 1 |
| XB628 | Exelixis | Phase 1 |
| XB371 | Exelixis | Phase 1 |
| Multiple Preclinical Programs | Perspective Therapeutics | Preclinical |
| Pre-Targeting Platform | Perspective Therapeutics | Preclinical |
| VDC Platform | Aura Biosciences | Pre-clinical/Discovery |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |